TLX provided an update on quarterly activities and Appendix 4C for June quarter

Telix Pharmaceuticals Limited (ASX: TLX) has released its quarterly activities and Appendix 4C quarterly cash flow statement for the quarter ended 30 June 2022:

• In the June quarter, the company reported total revenue of AU$22.5 million from global sales of illuccix, which is a ten-time increase over the prior quarter.
• It has completed the commercial launch of its lead prostate cancer imaging product, Illuccix, in the United States and progressively expanded from 117 to 140 radiopharmacy across Cardinal Health. The company has also added Jubilant and RLS pharmacies to its partnership network.
• On 01 June 2022, Telix Pharmaceuticals announced the appointment of Mr. Darren Smith as Group CFO and Mr. Kevin Richardson as CEO of Telix Americas.
• TLX reported an AU$1.9 million increase in customer receipt to AU$5.4 million. Other source of cash inflows includes A$17.2 million in government tax incentives for entitled R&D activities during the year ended 31 December 2021 along with AU$1.1 million of proceeds from options exercised.
• As of 30 June 2022, TLX had cash reserves of AU$122.6 million.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au